VE303
Phase 3Small molecule
VE303 is one of 53 small molecule programs targeting Encephalopathy. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
135 competitors in Encephalopathy
#DrugCompanyPhaseTrials
1Xifaxan
SSalix
Phase 3
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Alinia
RRomark Laboratories L.C.
Phase 3
PROCRIT
WWim Janssens
Phase 3
Cafcit
KKaken Pharmaceutical
Phase 3
Adakveo
NovartisPhase 2
Fludara
SanofiPhase 2
MS Contin
Merck & Co.Phase 2
VSL#3
CCD Pharma India Pvt. Ltd.
Phase 3
Erythropoietin-Beta
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Clostridioides difficile Infection2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VE303. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- VVedanta Biosciences, Inc.